Reliability of S100B in predicting severity of central nervous system injury - PubMed (original) (raw)

Review

Reliability of S100B in predicting severity of central nervous system injury

Stephen M Bloomfield et al. Neurocrit Care. 2007.

Abstract

S100B is a protein biomarker that reflects CNS injury. It can be measured in the CSF or serum with readily available immunoassay kits. The excellent sensitivity of S100B has enabled it to confirm the existence of subtle brain injury in patients with mild head trauma, strokes, and after successful resuscitation from cardiopulmonary arrest. The extent of S100B elevation has been found to be useful in predicting clinical outcome after brain injury. Elevations of S100B above certain threshold levels might be able to reliably predict brain death or mortality. A normal S100B level reliably predicts the absence of significant CNS injury. The specificity of S100B levels as a reflection of CNS injury is compromised by the findings that extra-cranial injuries can lead to elevations in the absence of brain injury. This potential problem can most likely be avoided by measuring serial S100B levels along with other biomarkers and carefully noting peripheral injuries. Serum markers GFAP and NSE are both more specific for CNS injury and have little to no extra-cranial sources. Sustained elevations of S100B over 24 h along with elevations of GFAP and NSE can more reliably predict the extent of brain injury and clinical outcomes. In the future, S100B measurements might reliably predict secondary brain injury and enable physicians to initiate therapeutic interventions in a timelier manner. S100B levels have been shown to rise hours to days before changes in ICP, neurological examinations, and neuroimaging tests. S100B levels may also be used to monitor the efficacy of treatments.

PubMed Disclaimer

Similar articles

• Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point.
  Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Rainey T, et al. Resuscitation. 2009 Mar;80(3):341-5. doi: 10.1016/j.resuscitation.2008.11.021. Epub 2009 Jan 15. Resuscitation. 2009. PMID: 19150161
• The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury.
  Žurek J, Fedora M. Žurek J, et al. Acta Neurochir (Wien). 2012 Jan;154(1):93-103; discussion 103. doi: 10.1007/s00701-011-1175-2. Acta Neurochir (Wien). 2012. PMID: 21976236
• Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury.
  Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM. Vos PE, et al. Neurology. 2004 Apr 27;62(8):1303-10. doi: 10.1212/01.wnl.0000120550.00643.dc. Neurology. 2004. PMID: 15111666
• Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis.
  Undén J, Romner B. Undén J, et al. J Head Trauma Rehabil. 2010 Jul-Aug;25(4):228-40. doi: 10.1097/HTR.0b013e3181e57e22. J Head Trauma Rehabil. 2010. PMID: 20611042 Review.
• Role of the S100B serum biomarker in the treatment of children suffering from mild traumatic brain injury.
  Filippidis AS, Papadopoulos DC, Kapsalaki EZ, Fountas KN. Filippidis AS, et al. Neurosurg Focus. 2010 Nov;29(5):E2. doi: 10.3171/2010.8.FOCUS10185. Neurosurg Focus. 2010. PMID: 21039136 Review.

Cited by

• How does extracerebral trauma affect the clinical value of S100B measurements?
  Ohrt-Nissen S, Friis-Hansen L, Dahl B, Stensballe J, Romner B, Rasmussen LS. Ohrt-Nissen S, et al. Emerg Med J. 2011 Nov;28(11):941-4. doi: 10.1136/emj.2010.091363. Epub 2010 Oct 14. Emerg Med J. 2011. PMID: 20947920 Free PMC article.
• Biospecimens and Molecular and Cellular Biomarkers in Aneurysmal Subarachnoid Hemorrhage Studies: Common Data Elements and Standard Reporting Recommendations.
  Chou SH, Macdonald RL, Keller E; Unruptured Intracranial Aneurysms and SAH CDE Project Investigators. Chou SH, et al. Neurocrit Care. 2019 Jun;30(Suppl 1):46-59. doi: 10.1007/s12028-019-00725-4. Neurocrit Care. 2019. PMID: 31144274 Free PMC article.
• Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas.
  Lange RP, Everett A, Dulloor P, Korley FK, Bettegowda C, Blair C, Grossman SA, Holdhoff M. Lange RP, et al. Cancer Invest. 2014 Oct;32(8):423-9. doi: 10.3109/07357907.2014.933237. Epub 2014 Jul 14. Cancer Invest. 2014. PMID: 25019213 Free PMC article.
• Effect of Erythropoietin on Serum Brain-derived Biomarkers after Carbon Monoxide Poisoning in Rats.
  Shahsavand S, Mohammadpour AH, Rezaee R, Behravan E, Sakhtianchi R, Moallem SA. Shahsavand S, et al. Iran J Basic Med Sci. 2012 Mar;15(2):752-8. Iran J Basic Med Sci. 2012. PMID: 23493953 Free PMC article.
• Trajectory analysis of serum biomarker concentrations facilitates outcome prediction after pediatric traumatic and hypoxemic brain injury.
  Berger RP, Bazaco MC, Wagner AK, Kochanek PM, Fabio A. Berger RP, et al. Dev Neurosci. 2010;32(5-6):396-405. doi: 10.1159/000316803. Epub 2010 Sep 18. Dev Neurosci. 2010. PMID: 20847541 Free PMC article.

References

1. 1. Resuscitation. 2002 Jun;53(3):251-7 - PubMed
2. 1. Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 - PubMed
3. 1. Int J Legal Med. 2000;113(2):70-5 - PubMed
4. 1. Glia. 1999 Sep;27(3):275-81 - PubMed
5. 1. Biochim Biophys Acta. 1999 Jul 8;1450(3):191-231 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Miscellaneous

  • NCI CPTAC Assay Portal